MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..

Estratab (.3 mg )

Company: Solvay Pharmaceuticals
Approval Status: Approved March 1998
Treatment for: prevention of osteoporosis
Areas: Diabetes / Endocrinology; Musculoskeletal; Pregnancy & Gynecology

| General Information | Clinical Results | Side Effects |

General Information

Estratab (.3 mg ) has been approved for the prevention of osteoporosis.

Clinical Results

In a two-year clinical trial, women on .3 mg Estratab tablets showed increased bone mineral density over baseline in the spine, hip, and whole body.

Side Effects

Women taking this low dose also experienced fewer side effects, such as headache, nausea, breast tenderness, and vaginal bleeding, than women on higher doses.

< back to top

Estratab Drug Information

The Estratab drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.